JP2016513644A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513644A5 JP2016513644A5 JP2016501386A JP2016501386A JP2016513644A5 JP 2016513644 A5 JP2016513644 A5 JP 2016513644A5 JP 2016501386 A JP2016501386 A JP 2016501386A JP 2016501386 A JP2016501386 A JP 2016501386A JP 2016513644 A5 JP2016513644 A5 JP 2016513644A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- pharmaceutical composition
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 48
- 239000000427 antigen Substances 0.000 claims description 47
- 102000036639 antigens Human genes 0.000 claims description 47
- 108091007433 antigens Proteins 0.000 claims description 47
- 108010067003 Interleukin-33 Proteins 0.000 claims description 25
- 102000017761 Interleukin-33 Human genes 0.000 claims description 25
- 101000998137 Homo sapiens Interleukin-33 Proteins 0.000 claims description 8
- 102000045906 human IL33 Human genes 0.000 claims description 8
- 238000010494 dissociation reaction Methods 0.000 claims description 7
- 230000005593 dissociations Effects 0.000 claims description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000005557 antagonist Substances 0.000 claims 12
- 239000013566 allergen Substances 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- 102100037850 Interferon gamma Human genes 0.000 claims 3
- 108010074328 Interferon-gamma Proteins 0.000 claims 3
- 108090000978 Interleukin-4 Proteins 0.000 claims 3
- 108010002616 Interleukin-5 Proteins 0.000 claims 3
- 206010035664 Pneumonia Diseases 0.000 claims 3
- 238000010171 animal model Methods 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 210000003651 basophil Anatomy 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000030961 allergic reaction Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- -1 bronchodilator Substances 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000000670 ligand binding assay Methods 0.000 claims 1
- 230000002912 lymphogenic effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 238000001525 receptor binding assay Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 230000002992 thymic effect Effects 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 239000012146 running buffer Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 101000998136 Mus musculus Interleukin-33 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778687P | 2013-03-13 | 2013-03-13 | |
| US61/778,687 | 2013-03-13 | ||
| US201361819018P | 2013-05-03 | 2013-05-03 | |
| US61/819,018 | 2013-05-03 | ||
| PCT/US2014/023930 WO2014164959A2 (en) | 2013-03-13 | 2014-03-12 | Anti-il-33 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019018423A Division JP6845876B2 (ja) | 2013-03-13 | 2019-02-05 | 抗ｉｌ−３３抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513644A JP2016513644A (ja) | 2016-05-16 |
| JP2016513644A5 true JP2016513644A5 (enExample) | 2017-04-06 |
| JP6479755B2 JP6479755B2 (ja) | 2019-03-06 |
Family
ID=50678269
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501386A Active JP6479755B2 (ja) | 2013-03-13 | 2014-03-12 | 抗ｉｌ−３３抗体及びその使用 |
| JP2019018423A Active JP6845876B2 (ja) | 2013-03-13 | 2019-02-05 | 抗ｉｌ−３３抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019018423A Active JP6845876B2 (ja) | 2013-03-13 | 2019-02-05 | 抗ｉｌ−３３抗体及びその使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9453072B2 (enExample) |
| EP (3) | EP4403570A3 (enExample) |
| JP (2) | JP6479755B2 (enExample) |
| KR (1) | KR102103159B1 (enExample) |
| CN (1) | CN105051063B (enExample) |
| AU (1) | AU2014248839B2 (enExample) |
| CA (1) | CA2902172C (enExample) |
| CL (2) | CL2015002469A1 (enExample) |
| DK (2) | DK3683235T3 (enExample) |
| EA (1) | EA031745B1 (enExample) |
| ES (2) | ES2983609T3 (enExample) |
| FI (1) | FI3683235T3 (enExample) |
| HR (2) | HRP20240774T1 (enExample) |
| HU (2) | HUE067119T2 (enExample) |
| IL (2) | IL240354A0 (enExample) |
| JO (1) | JO3532B1 (enExample) |
| LT (2) | LT2970460T (enExample) |
| MX (2) | MX377712B (enExample) |
| MY (3) | MY174740A (enExample) |
| PH (1) | PH12015501656A1 (enExample) |
| PL (2) | PL2970460T3 (enExample) |
| PT (2) | PT3683235T (enExample) |
| RS (2) | RS60503B1 (enExample) |
| SG (1) | SG11201505745WA (enExample) |
| SI (2) | SI3683235T1 (enExample) |
| TW (1) | TWI633119B (enExample) |
| UY (1) | UY35417A (enExample) |
| WO (1) | WO2014164959A2 (enExample) |
| ZA (1) | ZA201505376B (enExample) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230005405A (ko) | 2011-02-25 | 2023-01-09 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체 |
| KR102049122B1 (ko) | 2011-06-30 | 2019-11-26 | 추가이 세이야쿠 가부시키가이샤 | 헤테로이량화 폴리펩티드 |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| CN113416257A (zh) | 2011-11-30 | 2021-09-21 | 中外制药株式会社 | 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物 |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| TWI656880B (zh) | 2012-08-21 | 2019-04-21 | 法商賽諾菲生物技術公司 | 投與ｉｌ－４ｒ拮抗劑以治療或預防氣喘之方法 |
| KR102854939B1 (ko) | 2012-08-24 | 2025-09-03 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체 |
| WO2014104165A1 (ja) | 2012-12-27 | 2014-07-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| KR20150127591A (ko) | 2013-03-15 | 2015-11-17 | 리제너론 파아마슈티컬스, 인크. | Il-33 길항제 및 이의 용도 |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| BR112016013347B1 (pt) * | 2013-12-26 | 2023-12-12 | Mitsubishi Tanabe Pharma Corporation | Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos |
| KR102446386B1 (ko) | 2014-01-10 | 2022-09-22 | 아납티스바이오, 아이엔씨. | 인터루킨-33 (il-33)에 대한 항체 |
| CA2946511C (en) | 2014-04-21 | 2023-08-22 | The Childen's Hospital Of Philadelphia | Compositions and methods for treating cytokine-related disorders |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| CA2963991A1 (en) | 2014-09-29 | 2016-04-07 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
| SG11201703767XA (en) | 2014-11-10 | 2017-06-29 | Genentech Inc | Anti-interleukin-33 antibodies and uses thereof |
| US11708608B2 (en) * | 2014-11-10 | 2023-07-25 | Genentech, Inc. | Therapeutic and diagnostic methods for IL-33-mediated disorders |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| MX2017008978A (es) | 2015-02-05 | 2017-10-25 | Chugai Pharmaceutical Co Ltd | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos. |
| ES3000557T3 (en) | 2015-03-02 | 2025-02-28 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist |
| DK3277717T3 (da) * | 2015-03-31 | 2021-02-01 | Medimmune Ltd | En hidtil ukendt il33-form, muterede former af il33, antistoffer, assays og fremgangsmåder til anvendelse deraf |
| AU2016246590B2 (en) * | 2015-04-06 | 2021-10-07 | Meso Scale Technologies, Llc. | High throughput system for performing assays using electrochemiluminescence including a consumable shaking apparatus |
| TW202440904A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（二） |
| EA201890891A1 (ru) * | 2015-10-06 | 2018-09-28 | Ридженерон Фармасьютикалз, Инк. | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| US20190016795A1 (en) * | 2016-01-14 | 2019-01-17 | Anaptysbio, Inc. | Inhibition of allergic reaction using an il-33 inhibitor |
| US12297266B2 (en) | 2016-04-18 | 2025-05-13 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human CD40 and uses thereof |
| MA45294A (fr) * | 2016-04-22 | 2019-02-27 | Medimmune Llc | Plasticité fonctionnelle d'ilc2, immunité et copd |
| SG11201808693WA (en) * | 2016-04-27 | 2018-11-29 | Pfizer | Anti-il-33 antibodies, compositions, methods and uses thereof |
| HUE067896T2 (hu) | 2016-04-27 | 2024-11-28 | Abbvie Mfg Management Unlimited Company | Olyan betegségek kezelési módszerei az anti-IL-13 antitestek alkalmazásával, amelyekben az IL-13 aktivitás káros |
| CN116251182A (zh) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| CN117567621A (zh) * | 2016-10-13 | 2024-02-20 | 正大天晴药业集团股份有限公司 | 抗lag-3抗体及组合物 |
| JOP20190093A1 (ar) * | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| CN110494453B (zh) | 2017-02-10 | 2023-05-26 | 豪夫迈·罗氏有限公司 | 抗类胰蛋白酶抗体、其组合物及其用途 |
| CN108456251A (zh) * | 2017-02-21 | 2018-08-28 | 上海君实生物医药科技股份有限公司 | 抗pd-l1抗体及其应用 |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| CA3059350A1 (en) | 2017-04-13 | 2018-10-18 | Regeneron Pharmaceuticals, Inc. | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
| WO2018231827A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| KR20250041082A (ko) | 2017-07-06 | 2025-03-25 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| TWI850773B (zh) | 2017-08-31 | 2024-08-01 | 日商田邊三菱製藥股份有限公司 | 可溶性il-33受體的用途 |
| EP4640703A2 (en) | 2017-11-14 | 2025-10-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| EP3727629A1 (en) | 2017-12-22 | 2020-10-28 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| JP7349998B2 (ja) | 2018-01-31 | 2023-09-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法 |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| MX2020008291A (es) | 2018-02-09 | 2020-09-25 | Genentech Inc | Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos. |
| JP2021514609A (ja) | 2018-02-28 | 2021-06-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ウイルス混入物質を同定するためのシステムおよび方法 |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| MY202358A (en) | 2018-03-19 | 2024-04-24 | Regeneron Pharma | Microchip capillary electrophoresis assays and reagents |
| IL307286B1 (en) * | 2018-04-11 | 2025-11-01 | Regeneron Pharma | Methods and compositions for quantifying il-33 |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| CN118754986A (zh) | 2018-08-10 | 2024-10-11 | 中外制药株式会社 | 抗cd137抗原结合分子及其应用 |
| EP3774841A1 (en) | 2018-08-27 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| CA3100038A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| BR112021009543A2 (pt) | 2019-01-16 | 2021-08-17 | Regeneron Pharmaceuticals, Inc. | métodos para identificar tióis livres em um medicamento de proteína, de identificação de heterogeneidade de dissulfeto em um medicamento de proteína e para selecionar um medicamento de proteína, e, composição farmacêutica |
| TW202519263A (zh) | 2019-03-21 | 2025-05-16 | 美商再生元醫藥公司 | 含有抗il-33抗體之穩定調配物 |
| MX2021013427A (es) * | 2019-05-01 | 2022-01-31 | Sanofi Biotechnology | Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33. |
| SG11202110911RA (en) | 2019-05-13 | 2021-10-28 | Regeneron Pharma | Improved competitive ligand binding assays |
| EP3969475A4 (en) | 2019-05-15 | 2023-04-26 | Chugai Seiyaku Kabushiki Kaisha | An antigen-binding molecule, a pharmaceutical composition, and a method |
| CN115175700A (zh) | 2019-07-16 | 2022-10-11 | 赛诺菲生物技术公司 | 用于通过施用il-4r拮抗剂治疗或预防哮喘的方法 |
| PH12022550630A1 (en) | 2019-09-24 | 2023-03-27 | Regeneron Pharma | Systems and methods for chromatography use and regeneration |
| WO2021064452A1 (en) | 2019-10-03 | 2021-04-08 | Dasman Diabetes Institute | Method for preventing progression to type ii diabetes |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| JP2023501316A (ja) | 2019-11-04 | 2023-01-18 | メドイミューン・リミテッド | 腎機能障害を治療するための抗ｉｌ－３３治療薬 |
| TW202134261A (zh) | 2019-11-04 | 2021-09-16 | 英商梅迪繆思有限公司 | 使用il-33拮抗劑之方法 |
| US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| EP4081544A1 (en) * | 2019-12-23 | 2022-11-02 | Sanofi Biotechnology | Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist |
| CN113214395A (zh) * | 2020-01-21 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | 抗st2抗体及其应用 |
| WO2021150558A1 (en) | 2020-01-21 | 2021-07-29 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| EP4118236A1 (en) | 2020-03-13 | 2023-01-18 | MedImmune Limited | Therapeutic methods for the treatment of subjects with risk alelles in il33 |
| EP4118114A1 (en) * | 2020-03-13 | 2023-01-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| JP2023521061A (ja) | 2020-04-06 | 2023-05-23 | メドイミューン・リミテッド | Ｉｌ－３３軸結合アンタゴニストによる急性呼吸窮迫症候群の治療 |
| US20230192891A1 (en) * | 2020-04-13 | 2023-06-22 | Maddon Advisors Llc | ACE2-Targeted Compositions and Methods for Treating COVID-19 |
| BR112022022620A2 (pt) | 2020-05-11 | 2022-12-20 | Medimmune Ltd | Formulações de anticorpos anti-il-33 |
| EP4151654A4 (en) * | 2020-05-12 | 2024-11-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | St2 antigen binding protein |
| KR102789102B1 (ko) * | 2020-08-18 | 2025-03-28 | 성균관대학교산학협력단 | Il-33 항체 또는 이의 항원 결합 단편 |
| BR112023003273A2 (pt) | 2020-08-31 | 2023-05-02 | Regeneron Pharma | Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina |
| CN114249825A (zh) * | 2020-09-25 | 2022-03-29 | 三生国健药业（上海）股份有限公司 | 结合人il-33的抗体、其制备方法和用途 |
| US12239687B2 (en) | 2020-11-25 | 2025-03-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| KR20230121854A (ko) | 2020-12-17 | 2023-08-21 | 리제너론 파아마슈티컬스, 인크. | 단백질-캡슐화 마이크로겔의 제작 |
| AU2022209730A1 (en) | 2021-01-20 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| BR112023017442A2 (pt) | 2021-03-03 | 2023-09-26 | Regeneron Pharma | Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica |
| KR20230162932A (ko) | 2021-03-26 | 2023-11-29 | 리제너론 파아마슈티컬스, 인크. | 혼합 프로토콜 개발을 위한 방법 및 시스템 |
| EP4348234A1 (en) | 2021-06-01 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| CN113493513B (zh) * | 2021-06-30 | 2022-07-12 | 深圳大学 | 抗人il-33中和性自身抗体及其制备方法和应用 |
| CN113603775B (zh) * | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素-33单克隆抗体及其应用 |
| WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
| EP4405390A1 (en) | 2021-09-20 | 2024-07-31 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| WO2023059803A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
| CA3230984A1 (en) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Systems and methods of ph modeling and control |
| IL312372A (en) | 2021-10-26 | 2024-06-01 | Regeneron Pharma | Systems and methods for producing laboratory water and dispersing laboratory water at different temperatures |
| EP4430072A1 (en) | 2021-11-10 | 2024-09-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| JP7654346B2 (ja) * | 2022-03-03 | 2025-04-01 | ファイザー・インク | 多重特異性抗体およびその使用 |
| KR20240164561A (ko) | 2022-03-18 | 2024-11-19 | 리제너론 파아마슈티컬스, 인크. | 폴리펩타이드 변종을 분석하기 위한 방법 및 시스템 |
| TW202402790A (zh) | 2022-03-25 | 2024-01-16 | 英商梅迪繆思有限公司 | 減少呼吸系統感染之方法 |
| CN119923406A (zh) | 2022-08-19 | 2025-05-02 | 免疫医疗有限公司 | 选择患者以用il-33轴拮抗剂进行治疗的方法 |
| JP2026500269A (ja) | 2022-12-16 | 2026-01-06 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | クロマトグラフィーカラムの完全性を評価するための方法及びシステム |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| WO2024163708A1 (en) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| TW202446462A (zh) | 2023-02-22 | 2024-12-01 | 美商再生元醫藥公司 | 系統適用性參數及管柱老化 |
| TW202508625A (zh) | 2023-05-01 | 2025-03-01 | 美商再生元醫藥公司 | 使用苯酚或苯甲醇之多劑量抗體藥物產品 |
| KR102773101B1 (ko) | 2023-08-28 | 2025-02-26 | 서울대학교산학협력단 | 세포독성능을 갖는 제2형 선천성 림프구 세포, 이의 제조방법 및 용도 |
| JP7668943B2 (ja) * | 2023-08-30 | 2025-04-25 | ファイザー・インク | 多重特異性抗体およびその使用 |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| WO2025064403A2 (en) | 2023-09-18 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| US20250129117A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| TW202535934A (zh) | 2023-11-02 | 2025-09-16 | 美商再生元醫藥公司 | 利用應力來降低脂酶活性的方法 |
| WO2025120567A1 (en) | 2023-12-07 | 2025-06-12 | Medimmune Limited | Method of treatment of asthma |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| TW202540173A (zh) | 2024-04-04 | 2025-10-16 | 英商梅迪繆思有限公司 | 治療及選擇對象之方法 |
| WO2025242618A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Bronchiectasis treatment |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US550362A (en) | 1895-11-26 | crosby | ||
| US1000056A (en) | 1910-11-03 | 1911-08-08 | Carlos Van Bergh | Threshing-machine. |
| US1001164A (en) | 1911-06-09 | 1911-08-22 | Arthur W Porter | Cotton-sweep. |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US5576191A (en) | 1994-06-17 | 1996-11-19 | Immunex Corporation | Cytokine that binds ST2 |
| AU2003299441A1 (en) | 2002-12-19 | 2004-07-14 | Centre National De La Recherche Scientifique - Cnrs | Nf-hev compositions and methods of use |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
| US8865645B2 (en) | 2006-05-24 | 2014-10-21 | Biogen Idec Ma Inc. | Method of treating lung fibrosis using ST2 polypeptide |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| US8119771B2 (en) | 2007-04-26 | 2012-02-21 | The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | Products for altering IL-33 activity and methods thereof |
| JP2010527936A (ja) | 2007-05-18 | 2010-08-19 | メディミューン，エルエルシー | 炎症性疾患におけるｉｌ−３３ |
| JP2011500748A (ja) | 2007-10-26 | 2011-01-06 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | 神経変性障害の治療におけるｃａｓｐａｓｅＩ−依存性サイトカインの阻害剤 |
| EP2475388B1 (en) | 2009-09-10 | 2017-11-08 | Merck Sharp & Dohme Corp. | Use of il-33 antagonists to treat fibrotic disease |
| US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| KR20150127591A (ko) | 2013-03-15 | 2015-11-17 | 리제너론 파아마슈티컬스, 인크. | Il-33 길항제 및 이의 용도 |
| BR112016013347B1 (pt) | 2013-12-26 | 2023-12-12 | Mitsubishi Tanabe Pharma Corporation | Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos |
| KR102446386B1 (ko) | 2014-01-10 | 2022-09-22 | 아납티스바이오, 아이엔씨. | 인터루킨-33 (il-33)에 대한 항체 |
-
2014
- 2014-03-09 JO JOP/2014/0080A patent/JO3532B1/ar active
- 2014-03-11 TW TW103108304A patent/TWI633119B/zh active
- 2014-03-12 HR HRP20240774TT patent/HRP20240774T1/hr unknown
- 2014-03-12 US US14/205,512 patent/US9453072B2/en active Active
- 2014-03-12 MY MYPI2015702406A patent/MY174740A/en unknown
- 2014-03-12 PT PT201598711T patent/PT3683235T/pt unknown
- 2014-03-12 CN CN201480014548.XA patent/CN105051063B/zh active Active
- 2014-03-12 KR KR1020157021200A patent/KR102103159B1/ko active Active
- 2014-03-12 ES ES20159871T patent/ES2983609T3/es active Active
- 2014-03-12 MY MYPI2022005368A patent/MY209528A/en unknown
- 2014-03-12 JP JP2016501386A patent/JP6479755B2/ja active Active
- 2014-03-12 LT LTEP14722008.1T patent/LT2970460T/lt unknown
- 2014-03-12 RS RS20200801A patent/RS60503B1/sr unknown
- 2014-03-12 EA EA201591716A patent/EA031745B1/ru unknown
- 2014-03-12 HR HRP20200846TT patent/HRP20200846T1/hr unknown
- 2014-03-12 SI SI201432077T patent/SI3683235T1/sl unknown
- 2014-03-12 PT PT147220081T patent/PT2970460T/pt unknown
- 2014-03-12 WO PCT/US2014/023930 patent/WO2014164959A2/en not_active Ceased
- 2014-03-12 MY MYPI2019007720A patent/MY201923A/en unknown
- 2014-03-12 CA CA2902172A patent/CA2902172C/en active Active
- 2014-03-12 RS RS20240631A patent/RS65586B1/sr unknown
- 2014-03-12 PL PL14722008T patent/PL2970460T3/pl unknown
- 2014-03-12 SI SI201431574T patent/SI2970460T1/sl unknown
- 2014-03-12 ES ES14722008T patent/ES2804592T3/es active Active
- 2014-03-12 HU HUE20159871A patent/HUE067119T2/hu unknown
- 2014-03-12 FI FIEP20159871.1T patent/FI3683235T3/fi active
- 2014-03-12 EP EP24170532.6A patent/EP4403570A3/en active Pending
- 2014-03-12 SG SG11201505745WA patent/SG11201505745WA/en unknown
- 2014-03-12 PL PL20159871.1T patent/PL3683235T3/pl unknown
- 2014-03-12 LT LTEP20159871.1T patent/LT3683235T/lt unknown
- 2014-03-12 DK DK20159871.1T patent/DK3683235T3/da active
- 2014-03-12 EP EP14722008.1A patent/EP2970460B1/en active Active
- 2014-03-12 HU HUE14722008A patent/HUE051018T2/hu unknown
- 2014-03-12 MX MX2015010599A patent/MX377712B/es active IP Right Grant
- 2014-03-12 EP EP20159871.1A patent/EP3683235B1/en active Active
- 2014-03-12 DK DK14722008.1T patent/DK2970460T3/da active
- 2014-03-12 AU AU2014248839A patent/AU2014248839B2/en active Active
- 2014-03-13 UY UY0001035417A patent/UY35417A/es not_active Application Discontinuation
-
2015
- 2015-07-24 ZA ZA2015/05376A patent/ZA201505376B/en unknown
- 2015-07-24 PH PH12015501656A patent/PH12015501656A1/en unknown
- 2015-08-04 IL IL240354A patent/IL240354A0/en unknown
- 2015-08-17 MX MX2020012416A patent/MX2020012416A/es unknown
- 2015-09-04 CL CL2015002469A patent/CL2015002469A1/es unknown
-
2016
- 2016-08-26 US US15/248,348 patent/US10000564B2/en active Active
-
2018
- 2018-01-12 CL CL2018000101A patent/CL2018000101A1/es unknown
- 2018-05-14 US US15/979,187 patent/US10519230B2/en active Active
- 2018-09-13 IL IL261743A patent/IL261743B/en active IP Right Grant
-
2019
- 2019-02-05 JP JP2019018423A patent/JP6845876B2/ja active Active
- 2019-11-18 US US16/687,257 patent/US11104729B2/en active Active
-
2021
- 2021-07-29 US US17/388,322 patent/US12037388B2/en active Active
-
2024
- 2024-06-05 US US18/734,956 patent/US20240425580A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513644A5 (enExample) | ||
| US20230250164A1 (en) | IL-18 Binding Protein (IL-18BP) In Inflammatory Diseases | |
| JP6845876B2 (ja) | 抗ｉｌ−３３抗体及びその使用 | |
| CN110167963B (zh) | 治疗发炎病况的方法 | |
| JP7778701B2 (ja) | 抗ｓｔ２抗体及びその適用 | |
| JP2016515130A5 (enExample) | ||
| JP2020513404A5 (enExample) | ||
| JP2018509153A (ja) | Ｔｓｌｐ結合タンパク質 | |
| JP2022023049A (ja) | バイオ医薬組成物 | |
| JP2019534282A (ja) | 抗ｉｌ−３３抗体およびその使用 | |
| JP2016029027A (ja) | プロスタグランジンｅ２結合タンパク質およびこの使用 | |
| TW201620933A (zh) | 抗體－飛諾莫接合物 | |
| RU2009120202A (ru) | Способы и композиции для лечения и мониторинга лечения связанных с il-13 расстройств | |
| KR20150074179A (ko) | 리실 옥시다제-유사 2 (loxl2)와 관련된 치료 및 진단 방법 | |
| JP7224304B2 (ja) | 生物医薬組成物および関連の方法 | |
| JP2014530836A (ja) | 炎症障害治療用のｉｌ１７ｃのアンタゴニスト | |
| TW202304980A (zh) | 經修飾的抗ｔｓｌｐ抗體 | |
| KR20200010294A (ko) | 치료용 항-cd40 리간드 항체 | |
| CN105745225A (zh) | Nav1.7抗体和使用所述抗体的方法 | |
| CN104470540B (zh) | 抗-mif抗体和糖皮质激素的联合治疗 | |
| WO2017153426A1 (en) | Tslp binding proteins | |
| JP2018529704A (ja) | アトピー性皮膚炎の治療および／または予防のためのｉｌ−１７ｃの拮抗剤 | |
| US20230365712A1 (en) | Notch4 antibodies and uses thereof | |
| JP2022172170A (ja) | 治療抗ＩｇＥ抗体並びにその方法及び組成物 | |
| JPWO2020041537A5 (enExample) |